Skip to content

Degradation of the Anorexic Hormone Peptide YY

Degradation of the Anorexic Hormone Peptide YY

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02493959
Enrollment
8
Registered
2015-07-10
Start date
2014-05-31
Completion date
2015-07-31
Last updated
2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

PYY, Degradation, kinetics, men

Brief summary

Peptide YY (PYY) is a gastrointestinal hormone released from the enteroendocrine cell upon food intake. The N-terminal truncated form, PYY3-36, exerts anorexic effects. In this study we want to investigate the kinetics of PYY1-36 and PYY3-36 and to examine whether a C-terminally degraded metabolite, PYY3-34, is formed after infusion of PYY.

Interventions

BIOLOGICALPYY1-36 infusion

Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.

BIOLOGICALPYY1-36 + sitagliptin

Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.

BIOLOGICALPYY3-36 infusion

0.8 pmol/kg/min infusion of PYY3-36.

BIOLOGICALplacebo

Infusion of saline for 2 hrs.

Sponsors

University of Copenhagen
CollaboratorOTHER
Hvidovre University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy * Normal BMI (18.5-25kg/m2)

Exclusion criteria

* Diabetes Mellitus * Gastric bypass * Non-caucasian * Height changes \>3 kg within last two months * Hemoglobin \< 7.6 mmol/l * Chronic disease * Smoking * Regularly use of medicine * Drug abuse

Design outcomes

Primary

MeasureTime frame
PYY3-34 concentration0-240 min
Half-lives of PYY1-36 and PYY3-360-240 min

Other

MeasureTime frameDescription
Appetite and nausea scores0-240 minBetween infusion differences in VAS scores
Blood pressure0-240 minBetween infusion differences in blood pressure
Blood glucose0-240 minBetween infusion differences in blood glucose
Heart rate0-240 minBetween infusion differences in heart rate

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026